Bioventix Announcements

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc

(“Bioventix” or the “Company”)

Result of AGM

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting held earlier today, all resolutions put to shareholders were duly passed.

For further information please contact:

About Bioventix plc: 

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

Bioventix plc

(“Bioventix” or “the Company”)

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 22 November 2022 that on 21 November 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 50 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,724 pence per Ordinary Share (the “Purchase”). The Ordinary Shares were purchased under a dividend reinvestment plan (“DRIP”).

Following the Purchase, Bruce Hiscock has a beneficial interest in 750 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

For further information please contact:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, confirms that its Annual Report and Accounts for the year ended 30 June 2022 and the Notice of Annual General Meeting (“AGM”) has been posted to shareholders.

A PDF version of the 30 June 2022 Annual Report can be downloaded here.

Notice of AGM to be held 8th December 2022 can be found here and proxy forms available here.

The AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00 p.m. on 8 December 2022.

The Board continues to monitor the situation surrounding COVID-19 and the advice from the Government on public gatherings. If the Government’s guidance changes at any point prior to the AGM, such that shareholders are unable to attend in person, the Company will update shareholders through an announcement to the London Stock Exchange and on the Company’s website. In light of this uncertainty, the Board strongly encourages shareholders to submit a proxy vote in advance of the AGM and to appoint the Chairman of the AGM as their proxy, rather than a named person who, if circumstances change, may not the able to attend the AGM.

For further information please contact:

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

Bioventix plc

(“Bioventix” or “the Company”)

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has been notified that Bruce Hiscock, Chief Financial Officer of the Company, completed the following dealings in the Company’s ordinary shares of 5 pence in the Company (“Ordinary Shares”):

• the transfer, via sale and purchase, of 204 Ordinary Shares into his ISA. Mr Hiscock sold 204 Ordinary Shares at a price of £33.41 from an account in his own name and bought 204 Ordinary Shares at a price of £34.00 to be held in his ISA; and
• the additional purchase of 276 Ordinary Shares at a price of £34.00 into his ISA.

Following these transactions, Mr Hiscock’s total beneficial interest in the Company is now 700 Ordinary Shares, representing approximately 0.01 per cent. of the Company’s total issued share capital.

For further information please contact:

Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2022

Highlights:

• Revenue up 7% to £11.72 million (2021: £10.93 million)
• Profit before tax up 14% to £9.28 million (2021: £8.12 million)
• Cash at year end of £6.1 million (30 June 2021: £6.5 million)
• Second interim dividend of 74p per share (2021: 62p)
• Special dividend of 26p per share (2021: 38p)

Click here to download the full report.

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, is pleased to announce a trading update for the year ended 30 June 2022 (“FY2022”).

As announced in our interim results to 31 December 2021, we had a slow start to the financial year. However, in the second half, we have seen an improvement in performance and our trading result for FY2022 as a whole is likely to be significantly ahead of market expectations.

This improvement reflects a degree of recovery from the pandemic effects experienced since early 2020, and we hope that this recovery will prove to be sustained and long-lasting. We are pleased that the roll-out of high sensitivity troponin products, that are supported by our technology, has also matched our expectations.

In addition, our results are reported in UK Sterling and the recent fall in value of the UK Sterling against the US Dollar has had a positive effect. Approximately 50% of our revenues are linked to US Dollars and royalties received recently from customers in respect of our H2 sales have been converted at more favourable exchange rates.

Notice of Results

Bioventix expects to release FY2022 results on 24 October 2022.

For further information please contact:

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”), and is disclosed in accordance with the company’s obligations under Article 17 of MAR.

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc

(“Bioventix” or “the Company”)

Director Dealing

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 26 April 2022 that on 25 April 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 3 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,500 pence per Ordinary Share (the “Purchase”). The shares were purchased under a dividend reinvestment plan (DRIP).

Following the Purchase, Bruce Hiscock has a beneficial interest in 424 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

For further information please contact:

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”), and is disclosed in accordance with the company’s obligations under Article 17 of MAR.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them